Stay updated on aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page.

Latest updates to the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page
- Check6 days agoChange DetectedThe page now shows revision v3.5.4 instead of v3.5.3, representing an internal maintenance or update to the site's revision tracking.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision: v3.5.3 was added to the study record, replacing the previous Revision: v3.5.2. This signals a minor administrative update to the study metadata rather than any changes to the trial content or conduct.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedRevision updated: v3.5.0 was removed and v3.5.2 was added.SummaryDifference0.1%

- Check56 days agoChange DetectedFooter revision label updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check92 days agoChange DetectedAdded a Publications entry for the ADRISK trial publication (Annals of Oncology 2025) and a Study Results entry detailing 24-month outcomes. Removed Plan to Share IPD, Plan for IPD, and Product Manufactured in and Exported from the U.S. items.SummaryDifference0.9%

Stay in the know with updates to aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page.